RecruitingPhase 3NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
Amarillo, TX · Austin, TX · +137 more sites
5 recruiting obesity studies with a site in Sugar Land, TX.
Sponsor: Amgen
Amarillo, TX · Austin, TX · +137 more sites
Sponsor: Amgen
Austin, TX · Bellaire, TX · Dallas, TX · +68 more sites
Sponsor: Novo Nordisk A/S
Amarillo, TX · Austin, TX · +96 more sites
Sponsor: Novo Nordisk A/S
Amarillo, TX · Austin, TX · Brownsville, TX · +42 more sites
Sponsor: Ascletis Pharma (China) Co., Limited
Austin, TX · Brownsville, TX · DeSoto, TX · +81 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.